Department of Anesthesiology, Ningbo City First Hospital, Ningbo, Zhejiang, People's Republic of China.
Department of Anesthesiology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
Drug Des Devel Ther. 2022 Jan 19;16:237-247. doi: 10.2147/DDDT.S344309. eCollection 2022.
The main aim of the present study was to establish whether mesenchymal stem cell microvesicles (MSC MVs) exert anti-fibrotic effects and investigate the mechanisms underlying these effects in a mouse model of acute respiratory distress syndrome (ARDS)-associated early pulmonary fibrosis.
An ARDS-associated pulmonary fibrosis model was established in mice by an intratracheal injection of lipopolysaccharide (LPS). At 1, 3, and 7 days after LPS-mediated injury, the lungs of mice treated with MSC MVs and untreated controls were carefully excised and fibrosis was assessed based on the extent of collagen deposition. In addition, the development of epithelial-mesenchymal transition (EMT) was evaluated based on loss of E-cadherin and zona occludens-1 (ZO-1) along with the acquisition of α-smooth muscle actin (α-SMA) and N-cadherin. Nuclear translocation and β-catenin expression analyses were also used to evaluate activation of the Wnt/β-catenin signaling pathway.
Blue-stained collagen fibers were evident as early as 7 days after LPS injection. Treatment with MSC MVs suppressed pathological progression to a significant extent. MSC MVs markedly reversed the upregulation of N-cadherin and α-SMA and attenuated the downregulation of E-cadherin and ZO-1. The expression and nuclear translocation of β-catenin were clearly decreased on day 7 after MSC MV treatment.
Analyses indicated that MSC MVs could ameliorate ARDS-associated early pulmonary fibrosis via the suppression of EMT and might be related to Wnt/β-catenin transition signaling.
本研究的主要目的是确定间充质干细胞微囊泡(MSC MV)是否具有抗纤维化作用,并在急性呼吸窘迫综合征(ARDS)相关早期肺纤维化的小鼠模型中探讨其作用机制。
通过气管内注射脂多糖(LPS)建立 ARDS 相关肺纤维化模型。在 LPS 介导损伤后 1、3 和 7 天,仔细切除接受 MSC MV 治疗和未治疗对照小鼠的肺,并根据胶原沉积程度评估纤维化。此外,还根据 E-钙粘蛋白和封闭蛋白-1(ZO-1)的丢失以及α-平滑肌肌动蛋白(α-SMA)和 N-钙粘蛋白的获得来评估上皮-间充质转化(EMT)的发展。还使用核转位和β-连环蛋白表达分析来评估 Wnt/β-连环蛋白信号通路的激活。
早在 LPS 注射后 7 天,就可见蓝色染色的胶原纤维。用 MSC MV 治疗可显著抑制病理性进展。MSC MV 明显逆转了 N-钙粘蛋白和α-SMA 的上调,并减弱了 E-钙粘蛋白和 ZO-1 的下调。在 MSC MV 治疗后第 7 天,β-连环蛋白的表达和核转位明显减少。
分析表明,MSC MV 可通过抑制 EMT 来改善 ARDS 相关早期肺纤维化,并且可能与 Wnt/β-连环蛋白转换信号有关。